Navalkissoor, ShaunakMillar, Robert P.2026-04-022026-04-022025-03Navalkissoor, S. and Millar, R.P. (2025), Peptide receptor radionuclide therapy (PRRT) special issue. Journal of Neuroendocrinology, 37: e70014. https://doi.org/10.1111/jne.70014.0953-8194 (print)1365-2826 (online)10.1111/jne.70014http://hdl.handle.net/2263/109428DATA AVAILABILITY STATEMENT : Data sharing is not applicable to this article as no new data were created or analyzed in this study.Peptide receptor radionuclide therapy (PRRT), a form of radioligand therapy (RLT), is a well-established treatment in well-differentiated neuroendocrine tumour (NET), but RLT is being increasingly employed in other cancers such as prostatic cancer. PRRT is a type of molecular radiotherapy and uses the theranostics principle, where the same target molecule utilises different radionuclides for imaging and therapy. The imaging of this target molecule first identifies whether the tumour exhibits enough of the diagnostic radionuclide to indicate adequate concentration of the therapeutic radionuclide pair (beta or alpha or auger emitting radionuclide pair). In NETs, the target molecule is predominantly the somatostatin receptor (SSR). This special issue of the journal focuses predominantly on PRRT in NETs but also touches on current and potential utilisation in other cancers.en© 2025 British Society for Neuroendocrinology. This is the pre-peer reviewed version of the following article : Peptide receptor radionuclide therapy (PRRT) special issue. Journal of Neuroendocrinology, 37: e70014. https://doi.org/10.1111/jne.70014.. The definite version is available at : https://onlinelibrary.wiley.com/journal/13652826.EditorialPeptide receptor radionuclide therapy (PRRT)Radioligand therapy (RLT)Neuroendocrine tumour (NET)Postprint Article